MALATHION Drug Patent Profile

Which patents cover Malathion, and what generic alternatives are available?

Malathion is a drug marketed by Pharmobedient and Suven Pharms and is included in two NDAs.

The generic ingredient in MALATHION is malathion. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the malathion profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Malathion

A generic version of MALATHION was approved as malathion by SUVEN PHARMS on May 23^rd, 2012.

Summary for MALATHION

US Patents:	0
Applicants:	2
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MALATHION

Paragraph IV (Patent) Challenges for MALATHION

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OVIDE	Topical Lotion	malathion	0.50%	018613	1	2011-03-16

US Patents and Regulatory Information for MALATHION

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	MALATHION	malathion	LOTION;TOPICAL	078743-001	Mar 6, 2009		DISCN	No	No
Suven Pharms	MALATHION	malathion	LOTION;TOPICAL	091559-001	May 23, 2012		RX	No	Yes

Malathion Investment Analysis: Drug Fundamentals, Patent Risk, Market Outlook, and Commercial Exposure

Last updated: August 1, 2026

Malathion is an established organophosphate insecticide with limited pharmaceutical value and no meaningful patent-based investment moat. Its U.S. human-health product, Ovide malathion lotion 0.5%, is an old prescription treatment for head lice. The broader malathion market is agricultural and public-health focused, with commercial exposure tied primarily to pesticide manufacturers rather than specialty-pharmaceutical companies. The investment case depends on regulatory approvals, manufacturing economics, resistance patterns, and agricultural demand, not on pharmaceutical exclusivity.

What is malathion and how does it work?

Malathion is an organophosphate acetylcholinesterase inhibitor. It disrupts neural signaling in insects and kills lice through prolonged enzyme inhibition. The compound is used in three main settings:

Market	Use	Commercial importance
Agriculture	Insect control on fruits, vegetables, field crops, and ornamental plants	Largest market
Public health	Mosquito and vector-control programs	Material but procurement-driven
Human medicine	Topical treatment for head lice	Small niche

Ovide contains malathion 0.5% in a topical lotion. The U.S. Food and Drug Administration approved Ovide for head-lice treatment, and the product label instructs patients to apply the lotion to dry hair and scalp before washing it after a specified period.[1]

Malathion is converted to malaoxon, a more potent acetylcholinesterase inhibitor. Mammalian metabolism and detoxification are generally more efficient than insect metabolism, but excessive exposure can cause cholinergic toxicity. The pharmaceutical product therefore carries handling, flammability, and exposure warnings.[1]

What is the FDA regulatory status of malathion?

Ovide is a prescription drug regulated under an FDA new drug application. The product is identified as malathion lotion 0.5% and was approved decades ago.[1]

Key FDA facts

Item	Status
Active ingredient	Malathion
Dosage form	Topical lotion
Concentration	0.5%
Indication	Head-lice treatment
U.S. product	Ovide
FDA pathway	New drug application
Therapeutic class	Pediculicide
Biosimilar pathway	Not applicable
Primary commercial issue	Small market and generic substitution

The product has no biologic characteristics. Biosimilar competition is therefore irrelevant. Any competing product would proceed through a small-molecule generic, abbreviated new drug application, or another conventional drug-development pathway.

The agricultural uses are regulated separately by the Environmental Protection Agency under the Federal Insecticide, Fungicide, and Rodenticide Act. EPA registration is distinct from FDA approval and can be affected by environmental-risk reviews, worker-safety standards, residue tolerances, endangered-species assessments, and state-level restrictions.[2]

When does malathion lose exclusivity?

Malathion lost meaningful active-ingredient exclusivity many years ago. The compound was developed and commercialized long before the modern Hatch-Waxman patent framework. The original composition-of-matter protection is expired, and any early pharmaceutical patents would also be expired.

Ovide’s commercial protection is therefore based on:

• Brand recognition among prescribers and patients.
• Existing FDA approval.
• Manufacturing know-how.
• Distribution relationships.
• Regulatory compliance.
• Formulation and packaging execution.
• Physician familiarity with an established treatment.

The product does not have a current composition-of-matter patent moat comparable to newer dermatology or anti-infective products. Any remaining formulation, process, or use patents would need to be evaluated individually in the current FDA Orange Book and patent records. They would not restore exclusivity over malathion as an active ingredient.

What patents protect malathion and Ovide?

The active ingredient is not meaningfully protected by enforceable U.S. composition patents. Malathion is an old, off-patent small molecule.

Patent estate assessment

Patent category	Investment assessment
Composition of matter	Expired
Original synthesis patents	Expired
Agricultural-use patents	Expired or commercially immaterial
Ovide formulation patents	No apparent durable blocking position
Method-of-use patents	Limited value because head-lice treatment is established
Manufacturing patents	Potentially relevant to cost, purity, and scale, but unlikely to block generic entry
Packaging or device patents	Narrow and avoidable
Regulatory exclusivity	No material modern exclusivity expected

A generic entrant would not need to reproduce every commercial attribute of Ovide. It would generally need to demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA requirements for the approved topical product. The practical barrier is lower than for complex drug-device products, long-acting injectables, or highly specialized dermatology formulations.

What is the Orange Book status of Ovide?

Ovide is an FDA-approved prescription product associated with malathion 0.5% lotion. The relevant regulatory record is the FDA Drugs@FDA database and the current Orange Book.[3]

The commercial significance of the Orange Book listing is limited because:

1. Malathion itself is off patent.
2. Ovide has been marketed for decades.
3. Pediatric and topical products can face modest development barriers, but those barriers do not create durable exclusivity.
4. A generic challenger can target the approved formulation without developing a novel active ingredient.
5. The market is small enough that generic manufacturers may have limited incentive to invest in the product.

A small market can delay generic entry even when patent barriers are weak. That delay reflects economics rather than legal exclusivity.

How many patents cover malathion?

No meaningful count of active patents can be used to support a broad malathion investment thesis. The historical patent estate is extensive if one includes global synthesis, agricultural formulation, manufacturing, and use documents. Most such patents are expired or narrow.

The relevant distinction is between historical patent volume and enforceable commercial protection:

Measure	Assessment
Historical patent documents	Numerous globally
Active composition patents	None expected for the old active ingredient
Blocking Ovide patents	No apparent durable estate
Active process patents	Possible but narrow
Active agricultural formulation claims	Possible by product and jurisdiction
Patent-based pricing power	Low

Patent landscaping should focus on specific commercial formulations, manufacturing processes, and jurisdictions. A raw patent count would overstate protection.

Are there Paragraph IV challenges to Ovide?

A Paragraph IV challenge is possible because malathion is an old small molecule with a conventional topical dosage form. The commercial likelihood of a challenge depends on market size, expected reimbursement, manufacturing cost, and the incumbent’s ability to retain prescriptions.

Publicly visible evidence does not establish a major, current Paragraph IV campaign against Ovide comparable to high-revenue branded drugs. The absence of a prominent challenge does not indicate strong patent protection. It more likely reflects the limited addressable market and unattractive return on generic-development investment.

Generic-entry scenarios

Scenario	Probability assessment	Commercial effect
No generic launch	Plausible because of limited market size	Ovide retains niche pricing
One generic entrant	Most commercially credible	Substantial price pressure
Multiple generic entrants	Possible if demand improves	Rapid price erosion
OTC conversion	Unlikely without FDA action and sponsor investment	Could expand access but reduce prescription value
New branded formulation	Low probability	Requires differentiation from low-cost alternatives

The most likely generic threat is economic rather than litigation-driven. A single approved generic could materially reduce Ovide’s revenue because the product addresses a narrow condition and has limited brand-based differentiation.

What formulations are protected by malathion patents?

Malathion formulations can differ in concentration, solvent system, viscosity, odor, stability, packaging, and patient-handling characteristics. Those differences can create narrow formulation claims, but they do not generally create broad protection over the active ingredient.

Potential formulation variables include:

• 0.5% topical lotion.
• Solvent selection.
• Vehicle composition.
• Stability against hydrolysis.
• Flammability controls.
• Odor-reduction systems.
• Child-resistant packaging.
• Application and rinse instructions.
• Agricultural emulsifiable concentrates.
• Ultra-low-volume mosquito-control formulations.

The pharmaceutical product’s formulation has practical value because malathion is volatile, flammable, and unpleasant to handle. Those attributes may support brand retention, but they also create opportunities for a generic sponsor to develop a substantially equivalent formulation.

How strong is the patent estate for malathion?

The pharmaceutical patent estate is weak. The regulatory and manufacturing position is more relevant than the patent position.

Patent-strength scorecard

Factor	Assessment
Active ingredient protection	Very weak
Remaining term	No material term expected
Formulation differentiation	Low to moderate
Manufacturing complexity	Low to moderate
Regulatory substitution risk	Moderate to high
Generic litigation risk	Low to moderate
Pricing power	Low
Long-term pharmaceutical moat	Weak

Malathion differs from newer topical anti-infective drugs, which may rely on formulation patents, pediatric exclusivity, device protection, or multiple approved indications. Ovide has an established product history but lacks the layered protection common in newer branded medicines.

What is the competitive landscape for malathion?

Malathion competes against prescription and nonprescription head-lice treatments. The main alternatives include permethrin, pyrethrins with piperonyl butoxide, ivermectin lotion, spinosad topical suspension, benzyl alcohol lotion, and mechanical nit removal.

Product or ingredient	Position versus malathion
Permethrin	Widely available, low cost, resistance concerns
Pyrethrins	Established OTC option, allergy and resistance concerns
Ivermectin lotion	Prescription alternative with convenient use
Spinosad	Prescription product with strong efficacy and no nit-combing requirement in some use cases
Benzyl alcohol	Prescription treatment that kills lice but not eggs
Malathion	Effective established product, but odor, flammability, and handling reduce convenience

Resistance is a central market variable. The Centers for Disease Control and Prevention lists multiple approved treatment options and advises that treatment selection should account for resistance, reinfestation, and correct use.[4] Resistance can create episodic demand for malathion, but it does not guarantee durable growth because physicians can substitute among several products.

Agricultural malathion competes with newer synthetic insecticides, biological products, integrated pest-management programs, and other organophosphates. Its relative position depends on crop, pest, residue rules, resistance management, and price.

Which companies are exposed to malathion?

The pharmaceutical product has historically been associated with Taro Pharmaceuticals. Taro’s commercial exposure to Ovide is not equivalent to exposure to the global malathion pesticide market.

Agricultural production and distribution have involved companies such as FMC and other regional pesticide manufacturers. Corporate ownership, registrations, and product branding vary by country and can change through divestitures, licensing, and local registrations.

Exposure by business model

Company type	Exposure
Branded pharmaceutical marketer	Ovide sales and prescription demand
Generic drug manufacturer	Potential low-cost malathion lotion
Technical-grade pesticide producer	Agricultural and public-health demand
Formulator or distributor	Regional crop and vector-control sales
Crop-protection company	Portfolio contribution, usually not a standalone driver
Contract manufacturer	Capacity and margin exposure

Public companies generally do not disclose malathion revenue as a standalone line item. Investors should treat it as a minor product-level exposure unless a company’s filings identify a material concentration.

What licensing deals affect malathion?

Malathion does not appear to have a major current licensing structure comparable to innovative pharmaceutical products. Agricultural rights are typically managed through product registrations, distributor arrangements, local manufacturing agreements, and regional marketing rights.

The more relevant commercial arrangements are:

• Regional pesticide distribution agreements.
• Contract manufacturing of technical-grade material.
• Registration transfers.
• Portfolio acquisitions.
• Public-health procurement contracts.
• Branded-generic commercialization agreements.

Licensing is unlikely to create substantial value unless a company controls a differentiated formulation, a low-cost manufacturing process, or a strategically important regional registration.

What litigation affects malathion?

Malathion-related legal exposure is more likely to involve environmental contamination, occupational exposure, pesticide injury, labeling, or regulatory restrictions than pharmaceutical patent litigation.

Potential litigation categories include:

• Personal-injury claims.
• Worker-exposure claims.
• Environmental contamination claims.
• Failure-to-warn allegations.
• Product-liability actions.
• EPA registration challenges.
• State restrictions and endangered-species litigation.
• Generic patent litigation involving a specific Ovide formulation.

No widely reported, market-defining U.S. patent litigation campaign appears to establish a durable barrier around Ovide. Environmental and regulatory litigation remains more relevant to agricultural manufacturers.

What are the FDA, EPA, and regulatory risks?

FDA risks for Ovide include labeling compliance, manufacturing quality, adverse-event reporting, product shortages, and generic substitution. EPA risks for agricultural malathion include toxicology reassessment, environmental exposure, residue tolerances, worker protection, and restrictions on use.

EPA has evaluated malathion under pesticide-registration and risk-assessment processes. Organophosphate pesticides face sustained regulatory scrutiny because of acute toxicity, cumulative exposure, and ecological effects.[2]

Regulatory risk comparison

Risk	Pharmaceutical product	Agricultural product
FDA approval risk	Low for existing product	Not applicable
EPA registration risk	Not applicable	Moderate to high
Label restriction risk	Moderate	High
Environmental litigation	Low to moderate	Moderate to high
Generic substitution	Moderate to high	Not applicable
Manufacturing compliance	Moderate	Moderate
Pediatric safety scrutiny	Relevant	Not applicable

What manufacturing and intellectual-property barriers exist?

Malathion is not a highly complex active ingredient. Technical synthesis requires control of impurities, residual solvents, degradation products, and product stability, but it does not present the manufacturing barriers associated with peptides, antibodies, or complex sterile products.

The principal barriers are operational:

• Access to compliant chemical feedstocks.
• Control of impurities and malaoxon formation.
• Stable formulation design.
• Flammability and packaging compliance.
• EPA or FDA registration maintenance.
• Regional residue and worker-safety requirements.
• Reliable technical-grade production.
• Quality systems for pharmaceutical-grade material.

Manufacturing economics may provide more protection than patents. A small pharmaceutical market can discourage entrants, while the larger agricultural market can support multiple low-cost producers.

What revenue exposure does malathion create?

Ovide revenue is likely immaterial to a diversified pharmaceutical company. The product’s economics are constrained by:

• A narrow indication.
• Several competing treatments.
• Generic substitution.
• Limited treatment duration.
• Low annual treatment frequency.
• Sensitivity to payer and pharmacy substitution.
• Lack of patent-supported premium pricing.

Agricultural malathion can generate larger aggregate sales, but it is normally one product among many in a crop-protection portfolio. Revenue depends on:

• Crop acreage.
• Pest outbreaks.
• Weather.
• Commodity prices.
• Public-health spraying.
• Regulatory restrictions.
• Resistance management.
• Low-cost competition from China and India.
• Inventory cycles.

Malathion should therefore be modeled as a mature, cyclical chemical product rather than a growth pharmaceutical.

What generic launch risks exist for Ovide?

The principal downside risk is a single generic entrant. Because Ovide is a niche product, one competitor could gain substantial share without requiring a large market.

A generic launch could cause:

• Lower wholesale acquisition cost.
• Pharmacy substitution.
• Reduced brand prescriptions.
• Lower payer reimbursement.
• Increased pressure on distributor margins.
• Declining brand revenue despite stable patient volume.

The brand could retain share if physicians value its established efficacy, if generic supply is unreliable, or if the generic formulation has inferior odor, handling, or patient acceptance. Those factors offer commercial resistance but do not constitute durable legal protection.

How does malathion compare with newer lice treatments?

Factor	Malathion	Spinosad	Ivermectin lotion	Permethrin
Product age	Old	Newer	Newer	Old
Prescription status	Prescription	Prescription	Prescription	OTC and prescription forms
Nit-combing burden	May be required	Often reduced	Often reduced	Often required
Resistance profile	Resistance can occur	Different mechanism	Different mechanism	Resistance is widespread in some regions
Patent strength	Weak	Historically stronger	Historically stronger	Weak
Pricing power	Low	Higher	Higher	Low
Investment appeal	Limited	Product-specific	Product-specific	Limited

Malathion’s strategic value is defensive and niche. It may benefit when resistance undermines pyrethroid-based treatments, but its own use limitations constrain share gains.

What is the investment outlook for malathion?

The pharmaceutical investment outlook is weak. The product has no apparent active-ingredient patent protection, limited market size, and substantial substitution risk. A branded Ovide thesis would require evidence of durable supply constraints, a favorable reimbursement position, a successful lifecycle formulation, or a strategic acquisition at a low valuation.

The agricultural outlook is more relevant but remains mature. Malathion can generate dependable cash flow in selected crops and public-health programs, yet its long-term risk profile includes environmental regulation, product restrictions, competition from newer chemistry, and price pressure.

Investment conclusion

Investment factor	Rating
Revenue growth	Low
Patent protection	Very low
Regulatory risk	Moderate to high
Manufacturing moat	Low to moderate
Generic risk	Moderate to high
Market durability	Moderate
Strategic value	Regional or portfolio-specific
Standalone investment attractiveness	Low

Malathion is better viewed as a mature pesticide and niche prescription product than as an investable pharmaceutical platform. Potential value lies in low-cost manufacturing, regional registration assets, public-health procurement, or inclusion in a broader crop-protection portfolio.

Key Takeaways

• Malathion is an old organophosphate insecticide with a small human-health market.
• Ovide malathion lotion 0.5% is the principal U.S. pharmaceutical product.
• The active ingredient and original pharmaceutical protections are expired.
• The Orange Book and regulatory approval provide market access, not a durable patent moat.
• Biosimilar risk is irrelevant because malathion is a small-molecule drug.
• A single generic entrant could materially reduce branded Ovide revenue.
• Agricultural and public-health applications are commercially more important than the prescription market.
• EPA regulation, environmental litigation, residue limits, and manufacturing economics are the main investment variables.
• No major current patent-litigation thesis is apparent around Ovide.
• Malathion has low standalone pharmaceutical investment appeal.

FAQs

Is malathion still patented?

The original malathion active ingredient is off patent. Any surviving patents would be narrow formulation, process, packaging, or jurisdiction-specific rights rather than broad composition protection.

Is Ovide a biologic or biosimilar product?

No. Ovide contains the small-molecule active ingredient malathion. It is subject to conventional small-molecule drug regulation, and biosimilar competition does not apply.

Can a generic manufacturer launch malathion lotion?

Yes, subject to FDA approval requirements and any legally enforceable product-specific rights. The principal barrier is likely market economics rather than active-ingredient patent protection.

Is malathion more valuable as a pharmaceutical or pesticide?

Malathion is more commercially significant as an agricultural and public-health pesticide. The prescription head-lice market is narrow and highly substitutable.

What could increase malathion demand?

Demand could rise from insecticide resistance to competing treatments, mosquito-control programs, crop-pest outbreaks, or restrictions on alternative insecticides. These drivers are episodic and do not create durable pharmaceutical growth.

References

1. U.S. Food and Drug Administration. (n.d.). Ovide (malathion) lotion 0.5% prescribing information. FDA Drugs@FDA.
2. U.S. Environmental Protection Agency. (n.d.). Malathion: Reregistration and risk-assessment materials. U.S. EPA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
4. Centers for Disease Control and Prevention. (n.d.). Treatment of head lice. CDC.